Development of novel chronic GVHD treatment based on the effects of the new therapeutic agent on helper/regulatory T cells

• Project/Area Number: 17K09955
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Hematology
• Research Institution: Okayama University
• Principal Investigator: Hisakazu Nishimori 岡山大学, 大学病院, 助教 (70756064)
• Co-Investigator(Kenkyū-buntansha): 前田 嘉信 岡山大学, 医歯薬学総合研究科, 教授 (60403474)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: タミバロテン / Th1細胞 / Tｈ17細胞 / 制御性T細胞 / Th17細胞 / マウスモデル / 内科

Outline of Final Research Achievements

This study aims to control the balance of helper T cells and regulatory T cells to overcome chronic graft-versus-host disease (GVHD), a complication of allogeneic hematopoietic stem cell transplantation for hematological malignancies. We investigated what kind of cytokines and chemokines are involved based on the data obtained from the clinical trial and animal experiments on chronic GVHD.

Academic Significance and Societal Importance of the Research Achievements

慢性GVHDに関わるサイトカイン、ケモカインの動態を確認することができたため、慢性GVHD患者さんへの治療介入にあたり、これらのサイトカインを確認しながら治療することでより適切なマネジメントが可能となる。さらに、このデータを参考し、次の慢性GVHDに対する臨床試験を計画中であり、慢性GVHDに対する新たな治療開発に繋げることができた。

Research Products

• [Presentation] Venous Thromboembolism in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease Receiving Synthetic Retinoid Am80 (2017)
  • Author(s): 西森久和
  • Organizer: 第59回米国血液学会
  • Int'l Joint Research